Anlotinib combined with etoposide as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): Updated results from a phase II trial.

被引：0
|
作者：
Shen, Bo
Wu, Yuan
Shi, Lin
Pan, Banzhou
Yang, Kaihua
Wang, Qiong
Zhao, Weiqing
Han, Zhengxiang
Wang, Lifeng
Feng, Jifeng
机构：
[1] Jiangsu Canc Hosp, Nanjing, Peoples R China
[2] Jiangnan Univ, Hosp, Wuxi, Jiangsu, Peoples R China
[3] Jiangyin Peoples Hosp, Jiangyin, Peoples R China
[4] First Peoples Hosp Changzhou, Changzhou, Jiangsu, Peoples R China
[5] Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China
[6] Nanjing Univ, Drum Tower Hosp, Med Sch, Comprehens Canc Ctr, Nanjing, Peoples R China
[7] Nanjing Univ, Clin Canc Inst, Nanjing, Peoples R China
[8] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20610
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Anlotinib Combined with Etoposide as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Shen, B.
    Wu, Y.
    Shi, L.
    Feng, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S509 - S510
  • [2] Anlotinib combined with etoposide as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): A single-arm, prospective phase II study
    Shen, B.
    Wu, Y.
    Shi, L.
    Feng, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1040 - S1040
  • [3] The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
    Browne, C.
    Ayoube, T.
    Samarasinghe, N.
    Hussaini, K.
    Warner, A.
    Black, M.
    Palma, D. A.
    Raphael, J.
    Kuruvilla, M. S.
    Blanchette, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1065 - S1065
  • [4] Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
    Gao, F.
    Zhao, Y.
    Li, X.
    Li, Y.
    Ma, T.
    Li, Q.
    Tang, X.
    Han, X.
    Yi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1069 - S1069
  • [5] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
    Kong, Tiandong
    Chen, Lu
    Zhao, Xiaoli
    Duan, Fangfang
    Zhou, Hanli
    Wang, Lei
    Liu, Danna
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1095 - 1105
  • [6] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
    Tiandong Kong
    Lu Chen
    Xiaoli Zhao
    Fangfang Duan
    Hanli Zhou
    Lei Wang
    Danna Liu
    Investigational New Drugs, 2022, 40 : 1095 - 1105
  • [7] Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study
    Thomas, M.
    Ponce Aix, S.
    Navarro Mendivil, A.
    Riera Knorrenschild, J.
    Schmidt, M.
    Wiegert, E.
    Kapp, K.
    Mauri, C.
    Domine Gomez, M.
    Kollmeier, J.
    Sadjadian, P.
    Froehling, K-P.
    Huber, R. M.
    Wolf, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 599 - 599
  • [8] The efficacy and safety profile of anlotinib with etoposide plus cisplatin/carboplatin in treatment-naive extensive-stage small cell lung cancer(SCLC) patients: Results from a phase II single-arm trial.
    Deng, Pengbo
    Yang, Huaping
    Chen, Cen
    Hu, Chengping
    Cao, Liming
    Gu, Qihua
    An, Jian
    Li, Bin
    Tang, Yongjun
    Meng, Jie
    Feng, Juntao
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)
    Sequist, L. V.
    Chiang, A.
    Gilbert, J.
    Gordon, M.
    Conkling, P. R.
    Thompson, D.
    Marcoux, J. P.
    Antonia, S. J.
    Liu, B.
    Shames, D. S.
    Lopez-Chavez, A.
    O'Hear, C.
    Fasso, M.
    Gettinger, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] UPDATED PFS ANALYSIS OF TORIPALIMAB WITH ANLOTINIB AND CHEMOTHERAPY AS FIRST-LINE THERAPY IN PATIENTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC)
    Luo, Hao
    Jian, Dan
    Feng, Yan
    Zhong, Li
    Chen, Qian
    Guan, Wei
    Zhang, Shiheng
    Luo, Jiamin
    Yang, Xueqin
    Gong, Kan
    Xiong, Yanli
    Li, Mengxia
    Xu, Mingfang
    Pu, Yu
    Zhao, Liang
    Qian, Chengyuan
    Dai, Nan
    Wang, Dong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A490 - A490
12345